人福医药：Q3营收58.19亿元，同比下降7.36%

Core Viewpoint - Renfu Pharmaceutical (600079.SH) reported a decline in revenue for Q3 2025, while net profit showed growth, indicating mixed financial performance [1] Financial Performance - Q3 2025 revenue reached 5.819 billion yuan, a year-on-year decrease of 7.36% [1] - Net profit attributable to shareholders for Q3 2025 was 534 million yuan, an increase of 11.56% year-on-year [1] - For the first three quarters of 2025, total revenue was 17.883 billion yuan, down 6.58% year-on-year [1] - Net profit attributable to shareholders for the first three quarters was 1.689 billion yuan, reflecting a year-on-year growth of 6.22% [1]